FilingsTodayMetabiomed
At a glance
Metabiomed filed 58 disclosures in the last 12 months, including 16 insider, 3 buyback, 1 earnings and 1 5% holder. The most recent key filing was on Oct 2.
Revenue for 2025 was ₩103B, up 9.5% on 2024. Operating margin was 20.8% against 18.3% a year earlier. Debt was 49% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩51.4B and operating profit of ₩11.1B.
The 2025 annual report lists 345 employees with an average tenure of 6 years and average pay of ₩52.5M, #1337 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩342M each on average. It paid ₩105 per common share in cash dividends, against ₩30 a year earlier (+250%). 오석송 and related parties held 20.78% at year end.
From the 2025 annual report
Staff: 345 (185 men, 160 women), of whom 12 on fixed-term contracts. Total pay for the year: ₩18B. Directors and auditors: 5, paid ₩1.7B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩105 | ₩30 | ₩20 |
| Payout ratio | 25.9% | 3.1% | 4.5% |
| Yield (as filed) | 2.14% | 0.82% | 0.47% |
| Total cash dividends | ₩2.8B | ₩685M | ₩457M |
Largest shareholder
오석송 holds 19.95%; with 2 related parties the group holds 20.78% of common shares at year end (from 21.15% at the start of the year).
Individuals paid ₩500M or more
| 오석송 대표이사 | ₩1.2B |
Auditor: 삼덕회계법인 · opinion: Unqualified. The report includes an emphasis of matter.
Rankings: Operating margin #55 of 1,376
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.